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Abstract
Background: Healthcare resource utilisation for Alzheimer’s disease (AD) in China is not well understood. This
Delphi panel study aimed to describe the clinical management pathways for moderate and severe AD patients in
urban China and to define the amount and cost of healthcare resources used.
Methods: A panel of 11 experts was recruited from urban China to participate in two rounds of preparatory interviews.
In the first round, 9 physicians specialised in dementia gave a qualitative description of the clinical management of AD
patients. In the second round, 2 hospital administrators were asked about the cost of AD management and care.
Results from the interviews were discussed by the experts in a Delphi panel meeting, where consensus was reached
on quantitative aspects of AD management, including the rate of healthcare resource utilisation, the respective unit
costs and caregiving time.
Results: Interviewees reported that mild AD is under-recognised in China; most patients are diagnosed with
moderate to severe AD. Loss of independence and agitation/aggression are the main drivers for healthcare
resource utilisation and contribute to a heavier caregiver burden. It was estimated that 70 % moderate AD
patients are independent/non-aggressive at the time of diagnosis, 15 % are independent/aggressive, 10 % are
dependent/non-aggressive, and 5 % are dependent/aggressive. Dependent/aggressive AD patients are more
likely to be hospitalised (70–90 %) than accepted in a nursing home (0–20 %), while the opposite is true for
dependent/non-aggressive patients (5–35 % for hospitalisation vs. 80 % for nursing home). Independent AD
patients require 1–3 hours/day of caregiver time, while dependent patients can require up to 12–15 hours/day.
Experts agreed that AD complicates the management of age-related comorbidities, found in 70–80 % of all AD
patients, increasing the frequency and cost of hospitalisation.
Conclusions: The Delphi panel approach was an efficient method of gathering data about the amount of
healthcare resources used and associated costs for moderate and severe AD patients in urban China. The
results of this study provide a useful source of information for decision makers to improve future healthcare
policies and resource planning, as well as to perform economic evaluations of AD therapies.
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Background
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterised by gradual memory impairment, agnosia and
decline in cognitive function. In addition, AD patients
frequently present with behavioural changes and neuro-
psychiatric symptoms (NPS), such as apathy, depression,
agitation, aggression, insomnia, impaired motor coordin-
ation and delusions [1, 2]. Progressive deterioration impacts
on personal autonomy, with patients becoming increasingly
reliant on caregivers [3, 4]. In the final stages of AD,
patients lose their ability to communicate, fail to recognise
loved ones, become bedridden and require continuous care
[4]. AD is most prevalent among people aged 70–85 years
and affects around twice as many women as men [3, 5].
Approximately 5.7 million people in China are estimated to
have AD, more than any other country in the world [5].
AD diagnosis is usually made by primary care physicians
upon examining the patient’s medical history in consult-
ation with a close relative or caregiver, followed by cognitive
tests and physical examinations. Brain imaging procedures
can also be performed to identify brain changes responsible
for the symptoms [4]. Although there is no effective cure
for AD, pharmacologic agents, such as acetylcholinesterase
inhibitors and N-methyl-D-aspartate (NMDA) receptor
antagonists, can assist in symptom management by slowing
the progressive decline in cognitive function [4, 6, 7]. How-
ever, reports suggest that only 10 % of individuals with
dementia in China are diagnosed, of which 21 % are
prescribed medication [8–10].
The increasing life expectancy in China has led to a
growing concern over age-related diseases, of which AD
is predicted to have the greatest clinical, societal and
economic impact [5, 11]. In 2009, the total yearly cost of
dementia in China was estimated to be approximately
6.4 billion USD [11]. Thus, adequate provision of health-
care resources to AD is a growing problem.
The cost of AD care depends on disease severity and
therefore varies greatly [12, 13]. Since the majority of AD
patients in China (96 %) are cared for at home by family
members [14], the disease costs are associated with a sub-
stantial social burden—caregivers frequently report a high
level of emotional and physical stress [15–17]. Although
the economic impact of AD has been well-documented in
numerous countries [18–24], few cost-of-illness studies for
AD have been performed in China. To our knowledge, only
one study has investigated the healthcare resources used by
AD patients in China [25]. This survey, conducted in
2005–2006, considered 67 AD patients (13 mild, 37 moder-
ate and 16 severe) in one Shanghai hospital. Annual costs,
estimated by retrospective interviews, were significantly
associated with patients’ degree of cognitive impairment
and autonomy. Direct costs were similar between the differ-
ent disease stages, while indirect costs (mainly informal
caregiving) increased drastically with AD severity.
Healthcare policies and patient management in China
vary widely between different provinces and among
hospitals of the same province. Despite recent progress,
there are still substantial differences in the type and cost of
healthcare services provided, medical insurance schemes
and government investment in healthcare infrastructure
[26]. As a consequence, the pattern of healthcare resource
utilisation for AD in China is not well understood, prevent-
ing an adequate comparison of the cost-effectiveness of
pharmacological interventions.
When published information on a particular question
is limited, the Delphi panel method can be used to
obtain expert-validated evidence. In this type of study, a
panel of experts is interviewed about the topic under
research, and the combined responses are anonymised
and shared with all participants. The panel of experts
then review their initial responses in light of group-
wide choices until consensus is reached [27].
Due to the paucity of data on the healthcare resources
needed for AD in China, we conducted a Delphi panel
study to describe the typical clinical management
pathways for AD patients diagnosed by physicians
specialised in dementia care, focussing on urban areas of
China where pharmacological treatments are available.
In addition, we evaluate the impact of disease severity
and symptoms on healthcare resource utilisation and
amount of caregiving required. Thirdly, we determine
the unit costs of the healthcare resources associated with
the management of AD. The information obtained was
used to develop a health economic model to evaluate
the cost-effectiveness of pharmacological treatment for
moderate and severe AD patients in China [28].
Methods
Study overview
The process for this Delphi panel study started with two
preparatory rounds of interviews, to perform a qualita-
tive evaluation of the clinical management of moderate
and severe AD patients in China. In the first round of
interviews, experts were asked to describe the clinical
aspects of AD diagnosis and management. In the second
round, experts were asked to estimate the economic
costs associated with moderate and severe AD. All
information gathered was anonymised and combined for
discussion in the Delphi panel meeting, including diver-
ging opinions and unclear answers.
The interviews were followed by a final consensus
meeting, where the experts discussed their answers to
reach consensus on quantitative aspects of AD manage-
ment, including the distribution of AD patients across a
range of health states at diagnosis, the impact of disease
severity and symptoms on the amount of healthcare
resources required, and the unit cost of each healthcare
resource. The values agreed upon by the experts were to
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be used as inputs in a health economic model, designed
to evaluate the clinical and economic outcomes of
pharmacological treatment of moderate and severe AD
patients in China [28].
Participants
Nine physicians specialising in AD were selected to be
interviewed on the clinical management of disease. Physi-
cians were recruited based on their level of experience
(more than 10 years of clinical practice), their expertise in
treating AD patients and their understanding of the impact
of healthcare policies on patient management. The physi-
cians selected worked in a range of healthcare institutions,
including general and psychiatric wards, routinely met
patients covered by different reimbursement schemes and
were recruited from three tier 1 cities in China: Beijing,
Shanghai and Guangzhou. Tier 1 cities are large, densely
populated urban metropolises in China with major eco-
nomic, cultural and political influence. The average income
level in these cities is much higher than the national aver-
age income. Two general hospital administrators from
Beijing were interviewed to provide information on the
financial costs of AD. Both experts were selected based on
their general experience of managing the price of hospital
services and the invoicing process, and dealing specifically
with accounting and administrative matters associated with
AD in their healthcare institution. For the Delphi consensus
meeting, six experts from the previous interviews convened
in person to form the discussion panel, which included four
physicians and the two hospital administrators.
Preparatory interviews—qualitative description of AD
management
Round 1: clinical management and healthcare resource
utilisation
Expert physicians were interviewed individually by trained
interviewers in September/October 2013. A questionnaire
and a discussion guide were provided to each interviewer,
who received training on the disease area and how to ef-
fectively conduct the interviews. The questionnaire covered
four topics:
1. Diagnosis and referral process. These questions
aimed to identify the main reasons that motivate
undiagnosed patients to visit the physician, the
severity of disease at the time of diagnosis and the
subsequent referral pathways.
2. Course of illness. Interviewees were asked to describe
the typical course of disease progression observed
for AD patients in their practice.
3. Patient management. These questions were
concerned with the impact of disease severity on the
type of healthcare resources and caregiver support
typically required by AD patients.
4. Impact of specific AD symptoms on patient
management. Interviewees were asked to describe
how cognitive impairment, dependency and NPS
(such as agitation/aggression) influence the
management of AD patients.
Lastly, interviewees were asked to report whether they
believed their routine practice was different from the
common practice amongst their peers.
Round 2: costs associated with AD care
Hospital administrators were interviewed individually by
trained interviewers in October 2013. The following topics
were discussed: diagnostic procedures (such as positron
emission tomography [PET] and biological testing), hospi-
talisation and reimbursement rates. Interviewees were also
asked to report whether they believed the healthcare
resources available at their hospital were different from
the services routinely provided in similar hospitals. This
round of interviews helped to clarify the typical hospital
funding and invoicing process for healthcare services in
China (results not shown). This evidence was used by the
study moderator to inform the discussions held during the
Delphi consensus meeting.
Delphi consensus meeting
A Delphi panel meeting was organised in November
2013, where the experts were provided with an overview
of the qualitative interview results, followed by the draft
structure of a health economic model developed to
assess the clinical and economic outcomes of treating
moderate and severe AD patients in China. The health
economic model was structured to reflect the qualitative
results of the preparatory interviews; the panel of
experts was then asked to reach agreement on specific
data inputs for the model.
Firstly, the experts were asked to estimate the propor-
tion of moderate AD patients seen at diagnosis in each of
four possible health states, based on patients’ functional
independence and presence of agitation/aggression: 1.
independent and non-agitated/aggressive; 2. independent
and agitated/aggressive; 3. dependent and non-agitated/
aggressive; 4. dependent and agitated/aggressive. The
same categories were applied to severe AD patients,
resulting in four additional health states. Secondly, experts
evaluated the frequency of utilisation of different health-
care resources for AD patients in each health state over a
6-month period. Only healthcare resources associated
with the management of AD were considered in this
study. Lastly, experts were asked to reach consensus on
the unit cost of each healthcare resource used (in Chinese
Yuan Renminbi [RMB]).
A moderator familiar with Delphi panel methodology,
AD and health economics facilitated the discussions,
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which involved all six experts present at the meeting.
Each question addressed to the panel was discussed
until the answers converged towards consensus, which
was typically achieved within two to four rounds of
debate.
Results
Preparatory interviews—qualitative description of AD
management
All interviewed physicians stated that the clinical
practice described was representative of their health-
care institution.
1. Diagnosis of AD Patients
The typical clinical investigation process for AD
patients was described to start with registration at
the hospital, followed by a cognitive assessment,
brain imaging procedures and finally a diagnosis.
The vast majority of AD patients were considered to
be diagnosed in the geriatric or neurology
departments of general hospitals. Patients exhibiting
NPS are often first seen by psychiatrists, either in
specialised psychiatric hospitals, or in the psychiatric
department of general hospitals. However, this
pathway was considered to be associated with a risk
of misdiagnosis in about one third of cases.
All physicians agreed that mild AD is under-
recognised in China, as most patients only seek
treatment once moderate to severe symptoms have
developed. This delay in diagnosis particularly ap-
plies to patients coming from rural areas and those
with lower levels of education. In the opinion of the
interviewees, the social stigma associated with AD
and a general lack of awareness about dementia are
the main reasons behind the delayed diagnosis of
this disease in China.
The main reasons that motivate patients, or their
caregivers, to seek diagnosis are memory loss,
increased dependency and personality changes
(agitation/aggression and other NPS). According to
the interviewees, disease severity at diagnosis varied
widely across hospitals: an estimated one third to
one half of patients are diagnosed with mild AD,
while the remaining patients tend to be equally
distributed between the moderate and severe disease
stages. Neurology departments and specialised
psychiatric hospitals reported a higher proportion of
severe AD at diagnosis because patients are referred
to these services in response to more serious NPS,
which manifest in the more advanced stages of the
disease [29, 6].
2. Disease Progression
Patients with mild AD were reported to take on
average 3–5 years to reach the moderate disease
stage, and a further 2–5 years before progressing to
severe AD (Table 1).
3. Management of AD Patients after Diagnosis
The interviewees reported that the majority of AD
patients are not hospitalised upon diagnosis, due to
the lack of healthcare resources at most general
hospitals in China. In contrast, patients who first
visit the hospital due to NPS are usually referred to
psychiatric departments, where they are more likely
to remain hospitalised.
After diagnosis, patients are followed up on a regular
basis (outpatient visits every 2 weeks or once a
month). Diagnostic procedures are usually repeated
when patients come for their second visit, but not in
subsequent appointments. Brain imaging procedures
for diagnosis and monitoring vary widely across
hospitals. Magnetic resonance imaging (MRI) is the
most common procedure, while X-ray computed
tomography (X-ray CT) or positron emission tom-
ography (PET) may be performed, but are not rou-
tinely used.
According to the interviewees, the main drivers of
healthcare resource utilisation by AD patients are
the presence of NPS, such as agitation/aggression,
and loss of independence. These symptoms can lead
to hospitalisation and aggravate the burden on
caregivers. It was also reported that 70–80 % of AD
patients develop age-related comorbidities, such as
bone fractures, diabetes, chronic obstructive pul-
monary disease, heart failure, pneumonia and urin-
ary tract infection. Age-related comorbidities are a
frequent cause of hospitalisation and mortality
among elderly patients in general. However, it was
noted that AD complicates the clinical management
Table 1 Progression of AD and usual symptoms
Diagnosis 3–5 years after diagnosis 6–9 years after diagnosis ≥10 years after
diagnosis
30–40 % patients experience mild cognitive
impairments and/or personality changes for 1–2 years
before visiting the hospital.
30–40 % patients develop NPS
(e.g. anxiety, insomnia, distrust
of others)
30–40 % patients present more





About 50 % patients dependent
on caregivers
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of age-related comorbidities, increasing the amount
of healthcare resources required to manage those
conditions.
4. Caregiver Support
It was reported that most care is provided by unpaid
family members, who provide help with basic needs,
such as bathing, eating and dressing. Access to
nursing homes is limited by the families’ income, as
few people can afford formal caregiving, and by the
patients’ symptoms, since patients who suffer from
complete loss of autonomy or agitation/aggression
are less likely to be accepted in a nursing home.
However, most nursing homes only provide basic
care, with only a limited number of institutions
offering memory/cognitive exercises and
rehabilitation. Overall, as AD becomes more severe,
not only does the burden of caregiving increase, but
it also becomes more difficult to find nursing homes
or professional caregivers willing to care for such
patients, even at high salaries.
Delphi panel meeting
1. Distribution of AD Patients at Diagnosis
The panel of experts estimated the distribution of
moderate AD patients at the time of diagnosis
across four health states, defined by the level of
functional independence and agitation/aggression.
The majority of AD patients (70 %) were considered
to be independent and non-aggressive at the time of
diagnosis (Table 2).
2. Healthcare Resource Utilisation
The consensus reached on the healthcare resources
used by moderate and severe AD patients, according
to the level of functional independence and
agitation/aggression, is presented in Table 3. Overall,
dependent AD patients have a much greater
requirement for healthcare resources than
independent patients. The causes and duration of
hospitalisation were a major topic of debate among
the experts. Upon thorough discussion, the expert
panel recognised that the majority of hospital visits
after AD diagnosis are due to age-related comorbidi-
ties: AD patients with comorbidities are more likely
to be hospitalised, and for longer periods of time,
than non-AD patients with the same conditions.
This is particularly true for patients in the moderate
and severe stages of disease who suffer from agita-
tion/aggression and/or have lost functional inde-
pendence. Once this fact was acknowledged, experts
were able to reach consensus on the probabilities of
hospitalisation. For instance, it was agreed that
dependent/aggressive AD patients are more likely to
be hospitalised (70–90 % probability) than accepted
in a nursing home (0–20 % probability), while the
opposite is true for dependent/non-aggressive pa-
tients (5–35 % probability of hospitalisation vs. 80 %
probability of being accepted in a nursing home;
Table 3). The average length of hospitalisation was
considered to be 2 months.
3. Caregiver Time
The Delphi panel agreed that the amount of
caregiving time required increases as moderate AD
patients progress to severe stage of disease, due to
the gradual cognitive decline and loss of autonomy
(Table 3). AD patients with aggressive behaviours
require additional supervision, in order to prevent
self-harm or aggression towards others (Table 3).
4. Unit Cost of Healthcare Resources
The highest healthcare cost was attributed to
hospitalisation, estimated as costing up to 30,000
RMB/month, which includes all expenses associated
with the treatment of age-related comorbidities and
AD complications (Table 4). This was followed by
the cost of formal caregiving (6000 RMB/month),
provided either in a nursing home or by a profes-
sional caregiver, and thirdly by the costs associated
with the initial diagnostic procedures (Table 4).
Discussion
The results of the Delphi study reported here represent
the opinions of a panel of expert physicians and hos-
pital administrators, regarding the clinical management
and associated costs for moderate and severe AD
patients in urban China. When available evidence on a
given topic is lacking or contradictory, the Delphi panel
approach provides a validated method of combining
expert opinion into group consensus [27]. Consensus
does not mean that the correct answer has been found,
but rather that a level of participant agreement has
been reached [30].
Delphi panel studies have been widely used to
develop health economic models in a variety of disease
areas [31–35]. In developed countries, the availability
of medical insurance claims databases, prescription
monitoring programmes, disease registries, epidemio-
logical and cost-of-illness studies mean that Delphi
panels are now rarely necessary to obtain the data re-
quired to build a health economic model. In countries
where such information sources are still scarce, the
Delphi panel approach constitutes a valuable method
Table 2 Distribution of moderate AD patients at the time of
diagnosis
Independent Dependent
Non-aggressive 70 % 10 %
Aggressive 15 % 5 %
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of obtaining expert-validated data. In China, the Delphi
method has been used in previous analyses of healthcare
policy and resource utilisation [36–41], including a study
on the cost-effectiveness of different antipsychotic agents
in schizophrenia, where a panel of senior psychiatrists
estimated patients’ probability of response to treatment
and rates of relapse and hospitalisation [42].
Several studies in China and other countries have shown
that physicians (especially general practitioners) lack con-
fidence and expertise in diagnosing and managing AD
[43–45]. To ensure that the information obtained in this
study reflected the level of care provided to patients diag-
nosed with AD, we decided not to perform a random
participant recruitment. Although input from general
practitioners would have provided a more complete pic-
ture of AD care in China, this was beyond the intended
scope of our study. For these reasons, we selected experts
with a proven track record in the field of dementia, who
are responsible for the clinical management of a large
number of moderate and severe AD patients. Therefore,
the results of this study reflect the clinical practice per-
formed in the healthcare institutions represented by the
invited experts. Although only two hospital administrators
participated in the study, the physicians recruited were
also very well-informed about Chinese healthcare policies,
patient reimbursement schemes and the cost of diagnostic
procedures and other healthcare services. Although the
experts’ opinions were occasionally different, consensus
was easily reached upon debate during the Delphi panel
meeting. This suggests that, concerning AD management,
there are considerable similarities in terms of healthcare
policies and clinical practice across hospitals from tier 1
cities. Indeed, the heterogeneity of clinical practice in
China is caused mainly by a healthcare system that applies
dissimilar policies to different city levels [26].
All experts interviewed in this study agreed that
patients with mild AD remain largely under-recognised
in China. This is in line with a recent report suggesting
that the majority of individuals with dementia in China
are not formally diagnosed, especially in less developed
cities and rural areas [9]. The majority of the population
believes that the early signs of AD are a normal result of
Table 3 Healthcare resource utilisation
Independent Dependent
Healthcare resource Non-aggressive Aggressive Non-Aggressive Aggressive
Moderate AD patients
Hospitalisationa 0 % 5 % 5 % 90 %
Nursing homea 0 % 20 % 80 % 0 %
Caregiver timeb 1 3 4 10
Consultationsc 6 6 6 6
Brain imagingc 0 0 0 0
Cognitive assessment scalesc 1 1 1 1
Biological analysisc 1 1 1 1
Severe AD patients
Hospitalisationa 1 % 1 % 35 % 70 %
Nursing homea 0 % 20 % 80 % 20 %
Caregiver timeb 1 3 12 15
Consultationsc 6 6 6 6
Brain imagingc 0 0 0.35 0.35
Cognitive assessment scalesc 0 0 0 0
Biological analysisc 1 1 1 1
aProbability of using the healthcare resource over a 6 month cycle. bNumber of hours of caregiving required per day. cNumber of times the healthcare resource
is used.
Table 4 Unit cost of healthcare resources used by AD patients
in urban China
Healthcare Resource Unit cost
Diagnosis hospitalisation 1600 RMB
Hospitalisationa 30,000 RMB/month
Consultation (service charge only) 14 RMB
Biological analysis 500 RMB
MRI 1050 RMB
Cognitive assessment scale 100 RMB
Nursing home 6000 RMB/month
Caregiver salary 6000 RMB/month
aCost of hospitalisation for AD patients, including treatment for any
complications or comorbidities (the average length of hospitalisation is
2 months). MRI: magnetic resonance imaging; RMB: Chinese Yuan Renminbi
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the ageing process, and feelings of shame are common
amongst relatives of AD patients [10]. As a consequence,
most families only seek diagnosis once patients have lost
their autonomy and/or experience symptoms of moder-
ate to severe AD.
The presence of comorbidities, aggressive symptoms
and loss of functional independence were considered by
the Delphi panel to be the main determinants of health-
care resource utilisation. Since China still lacks adequate
healthcare resources and infrastructure for the care of
dementia patients [8, 46], the management of AD is a
serious issue. For instance, nursing homes providing
specialised dementia care are still very rare in China,
except in major urban centres [47, 48]. Although
severe, dependent and aggressive AD patients require
continuous care, they were considered much less likely
to be accepted in a nursing home than non-aggressive
or independent severe AD patients, a situation that
has been previously reported in a multinational Delphi
study [41].
Since caring for the elderly is viewed as the family’s
responsibility in China, most AD patients receive only
informal care from family members [8, 10, 49], which
implies that a growing proportion of China’s economic-
ally active population will be responsible for the care of
dementia patients [50]. As the disease progresses, an
increasing amount of time is spent by caregivers looking
after the patients, often at the expense of their own
health, well-being and financial stability [49, 51, 52].
Recent socioeconomic changes threaten to exacerbate
the situation. The migration of young adults to tier 1
cities (such as Beijing, Shanghai and Guangzhou) is pre-
dicted to result in large numbers of elderly people being
left behind to live on their own. Consequently, an in-
creasing number of patients will depend on formal care-
giving services, which are only starting to emerge in
China [50, 26]. In spite of these facts, experts in the field
of dementia are yet to agree on how to adequately quan-
tify the cost of informal caregiving. Consequently, we
were unable to obtain reliable cost estimates for this
important component of the societal burden of AD in our
discussions with the expert panel. Instead, we have
explored the cost of professional vs non-professional care
in a separate publication, describing the cost-effectiveness
of pharmacological treatment in AD [28].
The duration and cost of hospitalisation was one of
the most debated topics in the Delphi panel meeting.
Once hospitalisation was agreed to include any AD com-
plications and age-related comorbidities, the experts
were able to reach consensus on the average duration
and unit cost of this healthcare resource. Furthermore,
age-related comorbidities were recognised as the main
cause of hospitalisation, a fact that has been previously
reported [53, 54]. Patients without AD typically receive
treatment for most comorbidities in an out-patient
setting. In contrast, AD patients with the same comor-
bidities are more likely to be hospitalised, and for longer
periods of time, due to their cognitive impairment and
loss of independence. Consequently, the cost of hospital-
isation is much higher for AD patients than for non-AD
patients with the same comorbidities.
Although this study provides valuable information
about the clinical management of moderate and severe
AD in China, there is a need to consider its potential
limitations. Given that the experts selected for the
Delphi panel were recruited from tier 1 cities, the results
of this study apply predominantly to AD patients living
in urban areas of China. At present, there are still
substantial economic and infrastructural disparities in
China between economically developed regions and the
rest of the country [26]. Urban populations benefit from
higher average income levels, better access to healthcare
facilities and tend to spend more on medical services
than rural residents [48]. Thus, the rate of AD diagnosis
and the healthcare costs we reported are not representa-
tive of smaller cities and rural communities, meaning
that a substantial proportion of the AD patient popula-
tion in China was not included in our analysis. However,
the heterogeneity of care provided in rural areas would
have made it very difficult for the Delphi panel to reach
consensus. Since our objective was to obtain data inputs
for a health economic model measuring the clinical and
economic outcomes of treating AD pharmacologically,
restricting this study to urban AD patients was consid-
ered an acceptable limitation. We are also aware that
limiting our analysis of healthcare costs to the moderate
and severe stages of disease provides an incomplete
picture of the economic and societal burden of AD.
Additional studies are required to define the amount
and cost of healthcare resources used by mild AD pa-
tients in China. Lastly, it should also be noted that the
experts present at the Delphi panel meeting discussed
results face-to-face. While this allowed for in-depth
discussions and facilitated consensus, it may have inhib-
ited participants from sharing opinions perceived as con-
troversial or different to those of the wider group.
The cost estimates provided in this study were used in a
health economic model evaluating the cost-effectiveness
of pharmacological treatment for moderate and severe AD
patients in China [28]. For this reason, we only considered
the cost of healthcare resources associated with AD man-
agement and did not include indirect costs, such as travel
expenses and loss of productivity by patients and informal
caregivers [4], which can exceed the cost of medication
and other healthcare resources [25, 52]. Consequently, the
costs reported in this study should be viewed as low-end
estimates and may not represent the full economic burden
of the disease. Nevertheless, the consensus obtained in the
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Delphi meeting represents the varied clinical and aca-
demic experience of the expert panel and provides a
valuable depiction of everyday clinical practice in urban
Chinese hospitals regarding the care of AD patients.
Conclusions
The Delphi panel approach provided an efficient method
for collecting data and achieving consensus on the
clinical management and associated costs for AD
patients in urban China. The experts agreed that most
AD patients in urban China are diagnosed with moder-
ate to severe disease. Loss of independence, presence of
agitation/aggression and age-related comorbidities are
the main drivers of healthcare resource utilisation and
heavier caregiver burden. The majority of direct medical
costs were attributed to hospitalisation and formal care-
giving. Due to an ageing population, the cost of dementia-
related care already represents a major burden on the
Chinese economy. The results of this study provide a
valuable source of information for future health economic
models of AD in China. Such models will help decision
makers to improve healthcare resource allocation and
meet the needs of AD patients in a country where demen-
tia is a major public health priority.
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